All journal publications

Found 24 results. Export: Tagged | XML
Filters: author is Schellekens  [Clear All Filters]
2014
Halim, L.A., Brinks, V., Jiskoot, W., Romeijn, S., Praditpornsilpa, K., Assawamakin, A., Schellekens, H. , How Bio-questionable are the Different Recombinant Human Erythropoietin Copy Products in Thailand?, Pharmaceutical research, vol. 31, issue 5, pp. 1210-1218. DOI
Torosantucci, R., Brinks, V., Kijanka, G., Halim, L.A., Sauerborn, M., Schellekens, H., Jiskoot, W. , Development of a Transgenic Mouse Model to Study the Immunogenicity of Recombinant Human Insulin, Journal of pharmaceutical sciences, vol. 103, issue 5, pp. 1367–1374. DOI
2013
Kijanka, G., Jiskoot, W., Schellekens, H., Brinks, V. , Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice, Pharm Res, vol. 30, pp. 1553-1560. DOI
Sauerborn, M., van Beers, M.M., Jiskoot, W., Kijanka, G.M., Boon, L., Schellekens, H., Brinks, V. , Antibody Response Against Betaferon(R) in Immune Tolerant Mice: Involvement of Marginal Zone B-cells and CD4+ T-cells and Apparent Lack of Immunological Memory, J Clin Imm, vol. 33, no. 1, pp. 255-63. DOI
2012
Filipe, V., Jiskoot, W., Basmeleh, A.H., Halim, A., Schellekens, H. , Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice, mAbs, vol. 4, no. 6.
Van Beers, M.M., Gilli, F., Schellekens, H., Randolph, T.W., Jiskoot, W. , Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene, J Pharm Sci, vol. 101, issue 1, pp. 187-199. DOI
2011
Brinks, V., Jiskoot, W., Schellekens, H. , Immunogenicity of therapeutic proteins: the use of animal models, Pharm Res, vol. 28, no. 10, pp. 2379-85. DOI
van Beers, M.M., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., Jiskoot, W. , Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice, Pharm Res, vol. 28, no. 10, pp. 2393-402. DOI
Brinks, V., Hawe, A., Basmeleh, A.H.H., Joachin-Rodriguez, L., Haselberg, R., Somsen, G.W., Jiskoot, W., Schellekens, H. , Quality of Original and Biosimilar Epoetin Products, Pharmaceutical Research, vol. 28, no. 2, pp. 386-393. DOI
2010
van Beers, M.M., Jiskoot, W., Schellekens, H. , On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis, J Interferon Cytokine Res, vol. 30, no. 10, pp. 767-75. DOI
van Beers, M.M., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., Jiskoot, W. , Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice, Pharm Res, vol. 27, issue 9, pp. 1812-1824. DOI
van Beers, M.M., Sauerborn, M., Gilli, F., Hermeling, S., Brinks, V., Schellekens, H., Jiskoot, W. , Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta, J Immunol Methods, vol. 352, no. 1-2, pp. 32-7. DOI
Sauerborn, M., Brinks, V., Jiskoot, W., Schellekens, H. , Immunological mechanism underlying the immune response to recombinant human protein therapeutics, Trends Pharmacol Sci, vol. 31, no. 2, pp. 53-9. DOI
2009
Jiskoot, W., van Schie, R.M.F., Carstens, M.G., Schellekens, H. , Immunological Risk of Injectable Drug Delivery Systems, Pharmaceutical Research, vol. 26, no. 6, pp. 1303-1314. DOI
2008
Gilli, F., van Beers, M., Marnetto, F., Jiskoot, W., Bertolotto, A., Schellekens, H. , Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera, Journal of Immunological Methods, vol. 336, no. 2, pp. 119-126. DOI
Sauerborn, M., van Beers, M., Jiskoot, W., Schellekens, H. , Immunogenicity of therapeutic proteins: A 'classical' break of tolerance?, Wiener Klinische Wochenschrift, vol. 120, pp. 123-123.
2006
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M.F.B.G., Crommelin, D.I.A., Jiskoot, W. , Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation, Journal of Pharmaceutical Sciences, vol. 95, no. 5, pp. 1084-1096. DOI
Hermeling, S., Jiskoot, W., Crommelin, D.J.A., Schellekens, H. , Reaction to the paper: Interaction of polysorbate 80 with erythropoietin: A case study in protein-surfactant interactions, Pharmaceutical Research, vol. 23, no. 3, pp. 641-642. DOI
Schellekens, H., Jiskoot, W. , Eprex-associated pure red cell aplasia and leachates, Nature Biotechnology, vol. 24, no. 6, pp. 613-614.
Schellekens, H., Jiskoot, W. , Role of aggregation in immunogenicity of recombinant human proteins, Nephrology Dialysis Transplantation, vol. 21, pp. 318-318.
2005
Hermeling, S., Jiskoot, W., Crommelin, D., Bornaes, C., Schellekens, H. , Development of a transgenic mouse model immune tolerant for human interferon beta, Pharmaceutical Research, vol. 22, no. 6, pp. 847-851. DOI
Hermeling, S., Aranha, L., Damen, J.M.A., Slijper, M., Schellekens, H., Crommelin, D.J.A., Jiskoot, W. , Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b, Pharmaceutical Research, vol. 22, no. 12, pp. 1997-2006. DOI
2004
Hermeling, S., Crommelin, D.J.A., Schellekens, H., Jiskoot, W. , Structure-immunogenicity relationships of therapeutic proteins, Pharmaceutical Research, vol. 21, no. 6, pp. 897-903.
2003
Hermeling, S., Schellekens, H., Crommelin, D.J.A., Jiskoot, W. , Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity?, Pharmaceutical Research, vol. 20, no. 12, pp. 1903-1907.